


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-61 (Cancelled).

62 (New) A method for the prophylaxis and/or treatment of induced cell toxicity, comprising the step of administering a compound comprising a structure of the general formula (VI)



wherein

each R¹ and each R² independently are selected from C, S, N, O, optionally substituted with C, S, N, O, OH,

hydrogen, alkyl, alkenyl, alkynyl, phenyl, benzyl, amine (NH), halogen, substituted lower alkyl, aryl, heterocycloalkyl, heteroaryl, aryl-(C₁₋₄)-alkyl, heteroaryl-(C₁₋₄)-alkyl, heterocyclyl-(C₁₋₄)-alkyl, cycloalkylalkyl, cycloalkyl, optionally further substituted one or more times with C, S, N, O, OH, phenyl, amine (NH), halogen, substituted lower alkyl, aryl, heterocyclyl, heteroaryl, aryl-(C₁₋₄)-alkyl, heteroaryl-(C₁₋₄)-alkyl, heterocyclyl-(C₁₋₄)-alkyl, cycloalkylalkyl, cycloalkyl, alkoxy, carboxy, halogen, trifluoromethyl, cyano, amino, or nitro, and wherein

m is an integer of from 1 to 8,

n is an integer of from 1 to 8,

N' and N'' are nitrogen,

R³, R⁴, R⁵ and R⁶ are independently selected from C, S, N, O, OH, hydrogen, alkyl, alkenyl, alkynyl, phenyl, benzyl, amine (NH), halogen, substituted lower alkyl, aryl, heterocycloalkyl, heteroaryl, aryl-(C₁₋₄)-alkyl, heteroaryl-(C₁₋₄)-alkyl, heterocyclyl-(C₁₋₄)-alkyl, cycloalkylalkyl, cycloalkyl, optionally further substituted one or more times with C, S, N, O, OH, phenyl, amine (NH), halogen, substituted lower alkyl, aryl, heterocyclyl, heteroaryl, aryl-(C₁₋₄)-alkyl, heteroaryl-(C₁₋₄)-alkyl, heterocyclyl-(C₁₋₄)-alkyl, cycloalkylalkyl, cycloalkyl, alkoxy, carboxy, halogen, trifluoromethyl, cyano, amino, or nitro, or one or more of R³, R⁴, R⁵ and R⁶ is a chemical bond,

or a pharmaceutically acceptable addition salt or hydrate thereof,

or diaminomethane, 1,2-diaminoethane, 1,3-diaminopropane, 1,4-diaminobutane, 1,5-diaminopentane, 1,6-diaminohexane, 1,7-diaminoheptane, 1,8-diaminooctane,

or a pharmaceutically acceptable addition salt or hydrate thereof.

63 (New). The method according to claim 62, wherein said cell presents the receptor megalin and/or the receptor cubilin.

64 (New). The method according to claim 62, wherein at least one of R^1 or R^2 is C.

65 (New). The method according to claim 62, wherein R^1 and R^2 are C.

66 (New). The method according to claim 62, wherein at least one of R^1 or R^2 is S.

67 (New). The method according to claim 62, wherein R^1 and R^2 are S.

68 (New). The method according to claim 62, wherein at least one of R^1 and R^2 is N.

69 (New). The method according to claim 62, wherein R^1 and R^2 are N.

70 (New). The method according to claim 62, wherein at least one of R^1 and R^2 is O.

71 (New). The method according to claim 62, wherein R^1 and R^2 are O.

72 (New). The method according to claim 62, wherein the medicament is capable of binding to the receptor megalin and/or the receptor cubilin.

73 (New). The method according to claim 62, wherein the compound is selected from the group consisting of 3-methylamino-1-(4-methylpiperazino)-2-propanole, 4-piperazinoaniline, 1-(3-chlorophenyl)piperazine diHCl (m-CPP), piperazin-2-one-HCl, 2-[4-(2-aminoethyl)piperazin-1-yl] ethylamine, piperazine anhydrous, 2,4-diamino-6-phenyl-1,3,5-triazine, 3,5-diamino-1,2,4-triazole, 2,5-piperazinedione, piperazine, and piperazin-2-one-HCl, 1-(2-pyrimidyl)piperazine dihydrochloride, or is a pharmaceutically acceptable addition salt or hydrate thereof.

74 (New). The method according to claim 73, wherein the compound is selected from 2-[4-(2-aminoethyl)piperazin-1-yl] ethylamine, 3-methylamino-1-(4-methylpiperazino)-2-propanole, and piperazine.

75 (New). The method according to claim 62, wherein the compound is piperazine.

76 (New). The method according to claim 62, wherein the compound is selected from the group consisting of 1,7-diaminoheptane, 1,2-diaminoethane, 1,4-diaminobutane, 1,6-diaminohexane, and 1,5-diaminopentane.

77 (New). The method according to claim 62, wherein the compound is 1,6-diaminohexane.

78 (New). The method according to claim 62, wherein the cell is from the kidney and/or the inner ear.

79 (New). The method according to claim 62, wherein said compound in solution has at least one positive charge.

80 (New). The method according to claim 62, wherein said compound has a polybasic charge distribution.

81 (New). A compound having the general formula of



wherein

A is a compound as defined in claim 62, and wherein

X is a spacer,

q is an integer of 1-100,

p is an integer of 1-100.

82 (New). The compound according to claim 81, wherein the spacer is a covalent bond.

83 (New). The compound according to claim 81, wherein the spacer consists of from 2-12 atoms.

84 (New). Method for prophylaxis and/or treatment of induced cell toxicity comprising the step of administering a compound as defined in claim 81.

85 (New). A combination medicament comprising a compound as defined in claim 62 and a therapeutic agent for simultaneous, separate or sequential use in induced cell toxicity therapy.

86 (New). The combination medicament according to claim 85, wherein said cell presents the receptor megalin and/or the receptor cubilin.

87 (New). A pharmaceutical composition comprising a compound as defined in claim 81 and pharmaceutically acceptable carriers, excipients or diluents therefor.